Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Both Alzheimer's disease and senile dementia of the Alzheimer type (AD/SDAT) are progressive dementias characterized neuropathologically by the presence in the cerebral cortex of numerous neurofibrillary tangles and neuritic plaques. We use the abbreviation AD/SDAT to denote all such cases, irrespective of age of onset. Studies of neurotransmitter-related parameters in autopsied brain tissues from patients with AD/SDAT have, to date, been confined to five putative transmitter systems. Acetycholine-releasing neurones seem to be most markedly and consistently affected, as judged by the extensive reductions in choline acetyltransferase (ChAT) and acetylcholinesterase activities that have been reported. Despite numerous studies, there is no consistent evidence for the involvement of neurones releasing dopamine, noradrenaline, serotonin, or gamma-aminobutyric acid in AD/SDAT, nor for loss of muscarinic cholinergic receptors. Thus, the involvement of cholinergic neurones in AD/SDAT seems to be specific. However, the possible involvement of neurones using other chemicals as transmitters has yet to be explored. The recent recognition of the existence of so-called 'peptidergic neurones' in the mammalian brain (for review see ref. 8) and the availability of radioimmunoassay (RIA) techniques for studying these peptides, have led us to begin a systematic investigation of neuropeptides in autopsied brain tissue from cases of AD/SDAT, and from neurologically normal individuals. We report here results obtained with a RIA for somatostatin, showing that somatostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ not only affects intracellular vesicular trafficking but could also affect primary cilia function directly or indirectly via its cognate binding receptors such as LRP1 [15, 50, 75].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“In addition, SST administration has been shown to be effective in improving cognitive impairment in AD patients [12, 15].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [15]
In the citing paper
“Additionally, AD patients have a specific loss of somatostatin-positive interneurons in the cortex [94] and hippocampus [95].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [94]
Citations
Cites
Hökfelt, T., Johansson, O., Ljungdahl, Å., Lundberg, J. M., & Schultzberg, M. (1980) · Nature · doi:10.1038/284515a0 · Cited by 1,547
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Neurotransmitter-related enzymes in senile dementia of the alzheimer type
Davies, P. (1979) · Brain Research · doi:10.1016/0006-8993(79)90336-6 · Cited by 634
Self-citationThe Prevalence and Malignancy of Alzheimer Disease: A Major Killer
Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040001001 · Cited by 619
Self-citationDementia of the Alzheimer Type
Terry, R. D., & Davies, P. (1980) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.03.030180.000453 · Cited by 529
Self-citationPrevalence and Malignancy of Alzheimer Disease
Lijtmaer, H., Fuld, P. A., & Katzman, R. (1976) · Archives of Neurology · doi:10.1001/archneur.1976.00500040088017 · Cited by 517
Self-citationNEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE
White, P., Goodhardt, M. J., Keet, J. P., Hiley, C. R., Carrasco, L. H., Williams, I. E. I., & Bowen, D. M. (1977) · The Lancet · doi:10.1016/s0140-6736(77)92114-6 · Cited by 489
Davies, P., & Verth, A. H. (1977) · Brain Research · doi:10.1016/0006-8993(77)90758-2 · Cited by 313
Self-citationRadioimmunoassay for GH-Release Inhibiting Hormone
Arimura, A., Sato, H., Coy, D. H., & Schally, A. V. (1975) · Experimental Biology and Medicine · doi:10.3181/00379727-148-38631 · Cited by 302
Research works printed but not linked: 1
- Wisniewski, H. M. & Terry, R. D. in Neurobiology of Aging (eds Terry, R. D. & Gershon, S.) 265–280 (Raven, New York, 1976).
Cited by
Items 501–600 of 889
Beal, M. F., Domesick, V. B., & Martin, J. B. (1985) · Brain Research · doi:10.1016/0006-8993(85)90690-0 · Cited by 22
Gauthier, S. G., Leblanc, R., Quirion, R., Carlsson, G., Beaulieu, M., Bouchard, R. W., Dastoor, D., Ervin, F. R., Gauthier, L., Gauvin, M., et al. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100036969 · Cited by 22
Somatostatin receptors in rat hippocampus: Localization to intrinsic neurons
Palacios, J. M., Reubi, J. C., & Maurer, R. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90392-7 · Cited by 22
Neuropeptides in degenerative disease of the central nervous system
Rossor, M. N., & Emson, P. C. (1982) · Trends in Neurosciences · doi:10.1016/0166-2236(82)90222-3 · Cited by 22
Immunocytochemistry of Regulatory Peptides
Polak, J. M., & Bloom, S. R. (1983) · Elsevier eBooks · doi:10.1016/b978-0-7236-0669-7.50018-0 · Cited by 22
Kokmen, E. (1984) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60340-1 · Cited by 26
Strittmatter, M., Hamann, G. F., Strubel, D., Cramer, H., & Schimrigk, К. (1996) · Journal of Neural Transmission · doi:10.1007/bf01273156 · Cited by 22
“Since it has been reported that somatostatin concentrations are significantly reduced in the frontal cortex and hippocampus of demented parkinsonians (Epelbaum et al., 1983; Beal et al., 1986) as well as in patients with senile dementia of Alzheimer type ( Davies et al., 1980; Davies and Perry, 1981) and that levodopa…”
BackgroundBurgos‐Ramos, E., Puebla‐Jiménez, L., & Arilla, E. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.11.019 · Cited by 21
Spangelo, B. L., Horrell, S. A., Goodwin, A. L., Shroff, S., & Jarvis, W. D. (2004) · NeuroImmunoModulation · doi:10.1159/000079414 · Cited by 24
Pharmacological characterisation of human cerebral cortex somatostatin SRIF1 and SRIF2 receptors
Piwko, C., Thoss, V. S., Schuepbach, E., Kummer, J., Langenegger, D., Probst, A., & Hoyer, D. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00004927 · Cited by 21
“In post-mortem brains and/or in cerebrospinal fluid (Patel et al. 1977) of patients with CNS disorders such as Alzheimer’s disease (Beal et al. 1985b; Davies et al. 1980), Huntington’s chorea (Beal et al. 1984; Nemeroff et al. 1983), multiple sclerosis (Sorensen et al. 1980), schizophrenia (Ferrier…”
Nakata, A., Saitō, H., & Nishiyama, N. (1996) · Brain Research · doi:10.1016/0006-8993(96)00233-8 · Cited by 23
Leake, A., & Ferrier, I. N. (1993) · Drugs & Aging · doi:10.2165/00002512-199303050-00003 · Cited by 23
Tetrahydroaminoacridine (THA) in Alzheimer's disease.
Byrne, J., & Arie, T. (1989) · BMJ · doi:10.1136/bmj.298.6677.845 · Cited by 23
Interactions of forebrain cholinergic and somatostinergic systems in the rat
Haroutunian, V. H., Kanof, P. D., & Davis, K. L. (1989) · Brain Research · doi:10.1016/0006-8993(89)91055-x · Cited by 21
Piwko, C., Thoss, V. S., Probst, A., & Hoyer, D. (1996) · Neuropharmacology · doi:10.1016/0028-3908(96)84643-0 · Cited by 21
Chapter 4: Cholinergic systems: human diseases, animal models, and prospects for therapy
Price, D. L., Koliatsos, V. E., & Clatterbuck, R. E. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)62380-8 · Cited by 22
Cortical and subcortical neuropeptides in Alzheimer's disease
Auchus, A. P., Green, R. C., & Nemeroff, C. B. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90102-3 · Cited by 22
Jang, J., Yeo, S., Baek, S., Jung, H. J., Lee, M. S., Choi, S. H., & Choe, Y. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01637-3 · Cited by 20
“Dysfunctional SOMs have been identified as a hallmark of AD, and loss of SOMs in the cortex is associated with AD pathologies [10, 15, 65].”
BackgroundCell-autonomous role of Presenilin in age-dependent survival of cortical interneurons
Kang, J., & Shen, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00419-y · Cited by 22
Paik, S., Somvanshi, R. K., & Kumar, U. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1045-5 · Cited by 21
Pinpointing the locus of GABAergic vulnerability in Alzheimer’s disease
Melgosa-Ecenarro, L., Doostdar, N., Radulescu, C. I., Jackson, J., & Barnes, S. J. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.06.017 · Cited by 22
Functional Implication of Taurine in Aging
Idrissi, A. E., Boukarrou, L., Splavnyk, K., Zavyalova, E., Meehan, E. F., & L’Amoreaux, W. J. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-75681-3_20 · Cited by 20
Chapter 9 Neuropeptide changes in aging and Alzheimer's disease
(1986) · Progress in Brain Research · doi:10.1016/s0079-6123(08)64302-2 · Cited by 20
Pathogenesis of Alzheimer's Disease — Beyond the Cholinergic Hypothesis: Discussion Paper
Harrison, P. J. (1986) · Journal of the Royal Society of Medicine · doi:10.1177/014107688607900612 · Cited by 23
Functional expression of brain cholecystokinin and bombesin receptors in Xenopus oocytes
Moriarty, T. M., Gillo, B., Sealfon, S. C., Roberts, J. L., Blitzer, R. D., & Landau, E. M. (1988) · Molecular Brain Research · doi:10.1016/0169-328x(88)90021-6 · Cited by 20
The Elusive Nature of Cerebellar Somatostatin Receptors: Studies in Rat, Monkey and Human Cerebellum
Piwko, C., Thoss, V. S., Probst, A., & Hoyer, D. (1997) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899709036616 · Cited by 20
Alhainen, K., Sirviö, J., Helkala, E., Reinikainen, K. J., & Riekkinen, P. J. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90223-g · Cited by 20
Moyse, E., Szigethy, E., Danger, J. M., Vaudry, H., Wenk, G. L., Beaudet, A., & Epelbaum, J. (1993) · Brain Research · doi:10.1016/0006-8993(93)91501-i · Cited by 20
Molecular pathology of the aging human brain
Selkoe, D. J. (1982) · Trends in Neurosciences · doi:10.1016/0166-2236(82)90198-9 · Cited by 25
Sodium Butyrate Stimulates Somatostatin Production by Cultured Cells*
Green, R., & Shields, D. (1984) · Endocrinology · doi:10.1210/endo-114-6-1990 · Cited by 20
Login, I. S., & Judd, A. M. (1986) · Endocrinology · doi:10.1210/endo-119-4-1703 · Cited by 20
Dokas, L. A., Zwiers, H., Coy, D. H., & Gispen, W. H. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90005-5 · Cited by 20
Sleep Disturbance and Alzheimer’s Disease: The Glial Connection
Sunkaria, A., & Bhardwaj, S. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03578-0 · Cited by 21
TSH responses to two TRH doses in men with alzheimer's disease
Lampe, T. H. (1988) · Psychoneuroendocrinology · doi:10.1016/0306-4530(88)90022-4 · Cited by 19
Non-NMDA receptor-mediated neuronal injury in Alzheimer's disease?
Choi, D. W. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90145-0 · Cited by 19
Quantitative autoradiographic study of somatostatin receptors in the adult human cerebellum
Laquerrière, A., Leroux, P., Bodénant, C., Gonzalez, B. J., Tayot, J. L., & Vaudry, H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90350-6 · Cited by 19
Epelbaum, J., Javoy-Agid, F., Enjalbert, A., Krantic, S. M., Kordon, C., & Agid, Y. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90242-0 · Cited by 19
Relationship of Down’s Syndrome to Alzheimer’s Disease
Rabe, A., Wisniewski, K. E., Schupf, N., & Wísniewski, H. M. (1990) · Springer eBooks · doi:10.1007/978-1-4613-0525-5_21 · Cited by 20
Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epileptics
Steardo, L., Barone, P., & Hunnicutt, E. J. (1986) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1986.tb04640.x · Cited by 19
Kecskés, M., Henn-Mike, N., Agócs-Laboda, Á., Szőcs, S., Petykó, Z., & Varga, C. (2020) · Communications Biology · doi:10.1038/s42003-020-01496-x · Cited by 18
Zhang, Z., Gao, L., Li, P., Jin, G., & Wang, J. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107401 · Cited by 20
“To be specific, the red regions produced by D 2 AM 1 contain the bilateral ventricles, bilateral hippocampi, and cerebral cortex, which are the biomarkers of AD and MCI [51 – 53].”
The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer?s disease
Doggrell, S. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.69 · Cited by 18
“Somatostatin immunoreactivity is lower in the hippocampi and cortices of AD patients than in age-matched controls [4].”
BackgroundBurgos‐Ramos, E., Hervás‐Aguilar, A., Puebla‐Jiménez, L., Boyano-Adánez, M. D. C., & Arilla, E. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21115 · Cited by 19
“Among the numerous neuropeptides produced in intrinsic hippocampal and cortical neurons, SRIF has been found to be the most consistently reduced in Alzheimer’s disease (AD) (Davies et al., 1980; Rossor et al., 1980; Wood et al., 1982; Reinikainen et al., 1987; Atack et al., 1988).”
BackgroundInfluentialInoue, T., Wang, F., Moriguchi, A., Shirakawa, K., Matsuoka, N., & Goto, T. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03241-8 · Cited by 18
Neuropathobiology of Senile Dementia and Mechanism of Action of Nootropic Drugs
Benešová, O. (1994) · Drugs & Aging · doi:10.2165/00002512-199404040-00002 · Cited by 19
Mair, R. G., Langlais, P. J., Mazurek, M. F., Beal, M. F., Martin, J. B., & McEntee, W. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90636-3 · Cited by 18
The effect of age on the response of the rat brains to continuous β-amyloid infusion
Nag, S., & Tang, F. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03172-3 · Cited by 18
Growth of brain tissue grafts is dependent upon host age
Eriksdotter, M., & Olson, L. (1989) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(89)90064-x · Cited by 18
Piwko, C., Thoss, V. S., SAMANIN, R., Hoyer, D., & Vezzani, A. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00304-1 · Cited by 18
Minger, S. L., & Davies, P. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90122-7 · Cited by 18
Self-citationReduced Proteins in Temporal Cortex in Alzheimer's Disease: An Electrophoretic Study
Borthwick, N. M., Yates, C. M., & Gordon, A. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb08780.x · Cited by 18
The Pathophysiological Basis of Parkinson’s Disease
Gerlach, M., & Riederer, P. F. (1993) · Milestones in drug therapy · doi:10.1007/978-3-0348-6348-3_2 · Cited by 18
Morgan, G. R., & Carlyle, B. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-57104-z · Cited by 19
Hirai, K., Kato, K., Nakayama, T., Hayako, H., Ishihara, Y., Goto, G., & Miyamoto, M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36533-4 · Cited by 20
Pharmacotherapy in Alzheimer's disease: Basis and rationale
Narang, P. K., & Cutler, N. R. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90022-9 · Cited by 21
Ohno, M., Yoshimatsu, A., Kobayashi, M., & Watanabe, S. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00230-0 · Cited by 17
Maeda, K., Kawata, E., Sakai, K., & Chihara, K. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90054-l · Cited by 17
Nag, S., & Tang, F. M. K. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00545-x · Cited by 17
Cerebrospinal fluid somatostatin in delirium
Koponen, H., Stenbäck, U., Mattila, E., Reinikainen, K. J., Soininen, H., & Riekkinen, P. J. (1989) · Psychological Medicine · doi:10.1017/s003329170002420x · Cited by 17
“In 55 patients (82%) delirium was associated with AD, PD or MID in all of which disorders a reduction of somatostatin-like immunoreactivity in CNS or CSF has been demonstrated (Rossor et al. 1980; Davies et al. 1980; Dupont et al. 1982; Epelbaum et al. 1983; Ferrier et al. 1983; Beal et al. 1986; Beal & Martin, 1986;…”
BackgroundCognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease
Waters, C. (1988) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100027694 · Cited by 17
Neurochemical Studies in Dementia
Rossor, M. N. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0933-8_3 · Cited by 22
Cholinergic Systems and Cholinergic Pathology
McGeer, P. L., & McGeer, E. G. (1984) · Springer eBooks · doi:10.1007/978-1-4684-4568-8_14 · Cited by 20
Acetylcholinesterase and somatostatin-immunoreactivity coexist in human neocortex
Nakamura, S., & Vincent, S. R. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90422-7 · Cited by 18
Unger, J. W., & Schmidt, Y. (1994) · Journal of Chemical Neuroanatomy · doi:10.1016/0891-0618(94)90005-1 · Cited by 17
Zafar, R., King, M. A., & Carney, P. R. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2011.12.035 · Cited by 16
Neurobiological Studies of Transmitter Systems in Aging and in Alzheimer‐Type Dementiaa
Price, D. L., Kitt, C. A., Struble, R. G., Whitehouse, P. J., Cork, L. C., & Walker, L. C. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb20798.x · Cited by 16
Post-Mortem Neurochemical Changes in Alzheimer's Disease Compared With Normal Ageing
Rossor, M. N., & Mountjoy, C. Q. (1986) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100037203 · Cited by 16
Hervás‐Aguilar, A., Puebla‐Jiménez, L., Burgos‐Ramos, E., Aguado‐Llera, D., & Arilla, E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.017 · Cited by 18
Mizuno, Y., Takahashi, K., Totsune, K., Ohneda, M., Konno, H., Murakami, O., Satoh, F., Sone, M., Takase, S., Itoyama, Y., et al. (1995) · Brain Research · doi:10.1016/0006-8993(95)00467-5 · Cited by 16
Hösli, E., & Hösli, L. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90152-x · Cited by 16
CSF neurotransmitter markers in Alzheimer's disease
Beal, M. F., & Growdon, J. H. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90006-0 · Cited by 19
Current and future approaches to therapy of Alzheimer's disease
Kan, J. P. (1992) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(92)90135-n · Cited by 16
Somatostatin and the Cerebral Cortex
Robbins, R. J. (1985) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-7886-4_12 · Cited by 16
Biologic Markers in Alzheimer's Disease
Thienhaus, O. J., Hartford, J. T., Skelly, M. F., & Bosmann, H. B. (1985) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1985.tb01782.x · Cited by 16
Muscarinic M1-Receptor Agonists: Potential in the Treatment of Alzheimer??s Disease
Cutler, N. R., & Sramek, J. J. (1995) · CNS Drugs · doi:10.2165/00023210-199503060-00006 · Cited by 16
Attempts to make models for Alzheimer's disease
Shiosaka, S. (1992) · Neuroscience Research · doi:10.1016/0168-0102(92)90037-d · Cited by 18
Lee, E. J., Bae, S., Suh, M., Choi, Y., Choi, Y., Hwang, D. W., & Lee, D. S. (2024) · BMC Genomics · doi:10.1186/s12864-024-10434-8 · Cited by 17
“However, the function of Sst-inhibitory neurons in the amygdala remains poorly understood [107].”
BackgroundBernardo, A. M., Marcotte, M. D., Wong, K. D., Sharmin, D., Pandey, K. P., Cook, J. M., Sibille, E. L., & Prévot, T. D. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.12.001 · Cited by 17
Gervais, É., Iloun, P., Martianova, E., Bessa, A. C. G., Rivest, S., & Topolnik, L. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25289 · Cited by 15
“In human tissue from AD cases and in tissue obtained from the mouse AD models, a large fraction of SOM+ interneurons was lost, while the surviving SOM+ cells showed damaged axons, a loss of axonal boutons and unstable dendritic spines (Chan-Palay, 1987; Davies et al., 1980).”
Bonanno, G., Gemignani, A., Schmid, G., Severi, P., Cavazzani, P., & Raiteri, M. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15558.x · Cited by 15
Autoradiographic analysis of somatostatin SRIF1 and SRIF2 receptors in the human brain and pituitary
Thoss, V. S., Piwko, C., Probst, A., & Hoyer, D. (1997) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/pl00004928 · Cited by 15
“Alterations in the density of somatostatin binding sites and in somatostatin immunoreactivity have been reported in a variety of CNS disorders, including depression, epilepsy, and neurodegenerative disorders such as Huntington’s, Alzheimer’s and Parkinson’s disease ( Davies et al. 1980; Beal et al. 1985a, 1985b; Nemer…”
Abnormalities in Non-Cholinergic Neurotransmitter Systems in Alzheimer’s Disease
Dewar, D., & McCulloch, J. (1994) · Springer eBooks · doi:10.1007/978-1-4615-6805-6_11 · Cited by 16
Chromatographic characterization of neuropeptides in post mortem human brain
Biggins, J. A., MCDERMOTT, J. R., Smith, A. I., Candy, J. M., Perry, R. H., Bateman, D. E., & Edwardson, J. A. (1984) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(84)90140-0 · Cited by 15
Influence of Gangliosides and Nerve Growth Factor on the Plasticity of Forebrain Cholinergic Neurons
Cuello, A. C., Maysinger, D., Garofalo, L., Tagari, P. C., Stephens, P. H., Pioro, E. P., & Piotte, M. (1987) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-08949-9_7 · Cited by 16
GABA Neurons and Their Cotransmitters in the Primate Cerebral Cortex
Jones, E. G. (1988) · Springer eBooks · doi:10.1007/978-1-4613-0925-3_9 · Cited by 16
Is it possible to design rational treatments for the symptoms of Alzheimer's disease?
Davies, P. (1985) · Drug Development Research · doi:10.1002/ddr.430050107 · Cited by 15
Self-citationOhno, M., Shibata, S., Yamamoto, T., & Watanabe, S. (1993) · Brain Research · doi:10.1016/0006-8993(93)91422-o · Cited by 17
Davies, P., Josef, J., & Thompson, A. (1981) · Brain Research Bulletin · doi:10.1016/0361-9230(81)90030-7 · Cited by 15
Self-citationStoessl, A. J. (1989) · Journal of Psychopharmacology · doi:10.1177/026988118900300208 · Cited by 15
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Sandoval, K. E., & WITT, K. A. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001117 · Cited by 19
“Initial studies us-ing AD post-mortem brain tissue identified that SRIF-like immunoreactivity was reduced in the cerebral cortex compared with age-matched controls (Davies et al., 1980; Rossor et al., 1980).”
Rajput, P. S., Billová, S., Patel, S. C., Kharmate, G., Somvanshi, R. K., & Kumar, U. (2009) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2009.05.004 · Cited by 15
“…(AIDS) encephalopathy, Down syndrome, multiple sclerosis and epilepsy as well as in psychiatric disorders such as schizophrenia and depression (Davies et al., 1980; Agren and Lundqvist, 1984; Beal et al., 1985; Vecsei et al., 1990; Banki et al., 1992; Krantic et al., 1992; Grouselle et…”
BackgroundSomatostatin and Alzheimer's disease
Vécsei, L., & Klivènyi, P. (1995) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(95)00640-7 · Cited by 14
Mapping of somatostatin receptor localization in rat brain: Forebrain and diencephalon
Katayama, S., Kito, S., Miyoshi, R., & Yamamura, Y. (1990) · Brain Research Bulletin · doi:10.1016/0361-9230(90)90087-g · Cited by 15
Somatostatin content and receptors in the cerebral cortex of depressed and control subjects.
Charlton, B. G., Leake, A., Wright, C., FAIRBAIRN, A. F., McKeith, I. G., Candy, J., & Ferrier, I. N. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.5.719 · Cited by 14
Biochemistry of Senile Dementia
DeKosky, S. T., & Bass, N. H. (1985) · Springer eBooks · doi:10.1007/978-1-4757-0797-7_23 · Cited by 16
Fine, A., Pittaway, K. M., de Quidt, M. E., Czudek, C., & Reynolds, G. P. (1987) · Brain Research · doi:10.1016/0006-8993(87)90801-8 · Cited by 14
Roy, A., DeJong, J., Gold, P. W., Rubinow, D., Adinoff, B. H., Ravitz, B., Waxman, R. P., & Linnoila, M. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01353.x · Cited by 14
Somatostatin Receptors in the Central Nervous System
Epelbaum, J. (1992) · Basic and clinical aspects of neuroscience · doi:10.1007/978-3-642-76948-1_2 · Cited by 14
Shi, Y., Liu, W., Yang, Y., Ci, Y., & Shi, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054839 · Cited by 14
“Furthermore, reduced expression of SST is a hallmark of various neurodegenerative and neuropsychiatric disorders, such as AD [55], PD [56], HD [57], major depressive disorder (MDD) [58], bipolar disorder, and schizophrenia (SCZ) [59].”
BackgroundNagarajan, R., Lyu, J., Kambali, M., Wang, M., Courtney, C. D., Christian, C. A., & Rudolph, U. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03586-3 · Cited by 16
“Interestingly, postmortem studies of patients with AD have shown reduced SOM expression in the hippocampus and cortical areas (Beal et al., 1985; Davies et al., 1980; Dournaud et al., 1994), and the decreased expression was correlated with the severity of cognitive deficits (Dournaud et al.”
Metadata
- Authors
- Davies, P., Katzman, R., & Terry, R. D.
- Affiliations
- Albert Einstein College of Medicine (US)
- Venue
- Nature
- Published
- 1980-11
- Volume
- 288
- Issue
- 5788
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034969383
- Cited by
- 882
- References
- 9
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 20 · 2023: 18 · 2022: 11 · 2021: 11 · 2020: 19 · 2019: 8 · 2018: 9 · 2017: 5 · 2016: 7 · 2015: 7 · 2014: 7 · 2013: 9 · 2012: 8
- FWCI
- 25.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- Alzheimer's disease, senile dementia of the Alzheimer type, somatostatin, somatostatin-like immunoreactivity, cerebral cortex, neuropeptides, peptidergic neurons, neurotransmitter systems, cholinergic neurons, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Alzheimer Disease, Cerebral Cortex, Choline O-Acetyltransferase, Dementia, Humans, Middle Aged, Radioimmunoassay, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.